1 active not recruiting, 1 completed, 1 enrolling by invitation. 2 Phase 2, 2 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Enrolling by invitation 1 |
| Phase 3 | 2 | Active not recruiting 1, Enrolling by invitation 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Han Ying: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis Characteristics Prednisone, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Phase 2 / Phase 3 | Enrolling by invitation | Han Ying | 244 | 2024-10-30 | 2026-10-29 |
| A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary Cholangitis Fenofibrate, UDCA (Ursodeoxycholic acid) - Primary Biliary Cholangitis (PBC) | Early Phase 1 | Completed | Han Ying | 30 | 2024-09-14 | 2026-08-05 |
| Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis Fenofibrate, Placebo, UDCA - Primary Biliary Cholangitis | Phase 2 / Phase 3 | Active not recruiting | Han Ying | 184 | 2023-08-21 | 2026-10-29 |
Fenofibrate (2) · Ursodeoxycholic Acid (2) · Prednisone (1)
China (3)